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Effect of vitamin C supplements on urinary oxalate and pH in Humans cannot synthesize vitamin C because they do
calcium stone-forming patients. not have the last enzyme in the biosynthetic pathway [1].
Background. The contribution of ascorbate to urinary oxa- The current recommended dietary allowance (RDA) forlate is controversial. The present study aimed to determine
vitamin C is 60 mg/day, but it is fairly common to findwhether urinary oxalate and pH may be affected by vitamin
subjects who because of health fads or the advice ofC supplementation in calcium stone-forming patients.
Methods. Forty-seven adult calcium stone-forming patients others, take megadoses of vitamin C on a daily basis in
received either 1 g (N  23) or 2 g (N  24) of vitamin C addition to the amount provided by their usual diet [2].
supplement for 3 days and 20 healthy subjects received 1 g. A Vitamin C can be metabolized to oxalate, which could24-hour urine sample was obtained both before and after vita-
increase oxalate excretion and hence the risk of calciummin C for calcium, oxalate, magnesium, citrate, sodium, potas-
oxalate stone formation [3, 4]. Therefore, stone formerssium, and creatinine determination. The Tiselius index was
used as a calcium oxalate crystallization index. A spot fasting are frequently advised to avoid vitamin C supplements.
morning urine sample was also obtained to determine the uri- Most of the oxalate found in the urine is usually formed
nary pH before and after vitamin C.
endogenously as a metabolic end product of glycoxylicResults. Fasting urinary pH did not change after 1 g (5.8 
acid (50% to 70%) and ascorbic acid (30% to 50%),0.6 vs. 5.8  0.7) or 2 g vitamin C (5.8  0.8 vs. 5.8  0.7). A
significant increase in mean urinary oxalate was observed in with minor contributions by gelatin, tryptophan, phenyl-
calcium stone-forming patients receiving either 1 g (50  16 vs. alanine, tyrosine, aspartic acid, creatinine, and purines [5].
31  12 mg/24 hours) or 2 g (48  21 vs. 34  12 mg/24 hours) Several studies have been performed in the last 40of vitamin C and in healthy subjects (25  12 vs. 39  13 mg/24
years in an attempt to determine the contribution ofhours). A significant increase in mean Tiselius index was ob-
high-dose vitamin C intakes to urinary oxalate excretionserved in calcium stone-forming patients after 1 g (1.43  0.70
vs. 0.92  0.65) or 2 g vitamin C (1.61  1.05 vs. 0.99  0.55) [6–17]. However, the data from various investigations are
and in healthy subjects (1.50  0.69 vs. 0.91  0.46). Ancillary contradictory, in part because of the difficulties regarding
analyses of spot urine obtained after vitamin C were performed
oxalate assay techniques [13–17]. In assays used beforein 15 control subjects in vessels with or without ethylenedi-
1987, artificial oxalate elevation occurred due to inadver-aminetetraacetic acid (EDTA) with no difference in urinary
oxalate between them (28  23 vs. 26  21 mg/L), suggesting tent ascorbate conversion to oxalate in stored samples,
that the in vitro conversion of ascorbate to oxalate did not occur. either because of the requirement of heating the urine
Conclusion. These data suggest that vitamin C supplementa- or because of the use of alkaline eluents [18, 19].tion may increase urinary oxalate excretion and the risk of
In healthy subjects, three short-term prospective stud-calcium oxalate crystallization in calcium stone-forming pa-
ies conducted in the last 6 years, with appropriate precau-tients.
tions to prevent nonenzymatic conversion of ascorbate
to oxalate, have determined the effects of ascorbate in-
take on oxaluria using doses ranging from 400 mg/dayVitamin C (ascorbic acid, ascorbate) is an essential
micronutrient involved in many biological and biochemi- to 4 g/day [14–16]. Levine et al [14] reported a significant
cal functions, acting as an electron donor or reducing increase of 33% in urinary oxalate after 1 g vitamin C
agent in chemical reactions [1]. supplement, whereas Liebman et al [15] and Auer, Auer,
and Rodgers [16] found that ascorbate doses from 2 to
4 g per day did not increase urinary oxalate. In a largeKey words: vitamin C, ascorbate, oxalate, urinary pH, kidney stone,
urinary calculi. epidemiologic study based on completion of dietary ques-
tionnaires, Curhan et al [4] did not observe a positiveReceived for publication June 24, 2002
association between consumption of vitamin C supple-and in revised form August 29, 2002
Accepted for publication October 16, 2002 ments and the risk of kidney stones in women.
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C supplementation on oxalate excretion in calcium-stone or 2 g (1000 mg twice a day) of vitamin C supplement
for 3 days. The 24-hour urine sample (post) was collectedforming patients [2, 3, 20, 21]. Three studies reported a
significant increase from 31% to 100% in urinary oxalate during day 3 of vitamin C supplementation. A morning
spot urine sample was also obtained after a 12-hour fastafter vitamin C supplement at doses from 0.5 to 2 g per
day [2, 3, 20]. On the other hand, Heckers et al [21] to determine the urinary pH both at baseline and in the
morning following day 3 of vitamin C supplementationfound no increase in urinary oxalate in seven calcium
stone-forming patients taking 1 g/day vitamin C. in the calcium stone-forming group. Twenty healthy sub-
jects (8 men and 12 women) received 1 g (500 mg twiceAlthough it has been suggested that vitamin C has
some effect on urinary acidification, reducing the urinary a day) vitamin C supplement for 3 days and a 24-hour
urine sample was obtained from them before and afterpH, the role of vitamin C as a urinary acidifier is still
controversial [22–30]. the supplementation.
Since few studies focusing on the effect of vitamin C
Effect of acid preservation on urinaryon urinary oxalate excretion in a population of calcium
oxalate determinationstone formers have been performed, the objective of the
present study was to determine whether urinary oxalate It has been suggested that, for a more reliable urinary
oxalate measurement, urine must be acidified in orderexcretion and pH could be affected by vitamin C supple-
mentation in calcium stone-forming patients. to ensure the complete dissolution of calcium oxalate
crystals, with hydrochloric acid (HCl) being used as a
preservative for urine collection. However, when acid is
METHODS
added to the plastic container before urine collection,
Protocol other parameters such as uric acid, sodium, and potas-
sium cannot be determined in the same urine sampleForty-seven adult calcium stone-forming patients (24
men and 23 women) participated in the study. Patients [32]. To test whether the addition of acid after the urine
specimen was delivered to the laboratory would interferewith diabetes, hyperparathyroidism, abnormal renal
function, or those taking drugs that could affect calcium with the urinary oxalate results, an additional group con-
sisting of 40 healthy subjects was submitted to two collec-metabolism were excluded. All patients were referred
to the Renal Lithiasis Unit of the Nephrology Division, tions of 24-hour urine on different occasions. The first
sample was obtained with acid preservation (HCl 6N,Universidade Federal de Sa˜o Paulo, Brazil, and were
sequentially enrolled in the study after a diagnosis of 20 mL/L) and the second in a dry plastic container, with
HCl added as soon as the urine sample was received atrenal stone has been established. The diagnosis of stone
disease was based on at least one of the following criteria: the laboratory. The mean oxalate excretion in these 40
control samples was similar for specimens previously(1) renal colic with confirmed hematuria, (2) voiding of
a calculus, (3) previous surgical or endoscopic removal acidified or not (27  14 vs. 29  12 mg/24 hours, P 
0.05, Wilcoxon test). Based on these results for the con-of stone(s), and/ (4) or radiographic (intravenous urogra-
phy or ultrasonography) evidence of stone(s). A written trol samples, 24-hour urine samples obtained from the
47 calcium stone-forming patients pre- and post-vitaminconsent was obtained from all patients and the local
Ethics Committee approved the study. A 24-hour urine C supplement intake were then collected into a dry plas-
tic container, with HCl added as soon as the urine samplesample was obtained from the 47 calcium stone-forming
patients both before (pre) and after (post) vitamin C was delivered to the laboratory. However, since in vitro
conversion of ascorbate to oxalate could be further in-supplementation for determination of calcium, oxalate,
sodium, potassium, urea, creatinine, magnesium, uric duced by a nonacid environment, the 47 calcium stone-
forming patients and the 20 controls were also asked toacid, and citrate. Calcium, oxalate, magnesium, and ci-
trate data were used to calculate the risk of calcium repeat the entire protocol, taking vitamin C supplements
for 3 additional days, and to collect another 24-houroxylate crystallization by the Tiselius index, calculated
according to the formula that follows: 1.9 calcium0.84 urine sample on day 3 in a vessel containing HCl.
oxalate  magnesium0.12  citrate0.22  volume1.03
Effect of EDTA preservation on urinary[31]. Patients were instructed to abstain from consuming
oxalate determinationoxalate-rich and vitamin C–rich foods (a listing of these
foods was provided), as well as dairy products for the It has been suggested that urine should be collected
with EDTA for ascorbate stabilization and to inhibit itstwo 24-hour periods of urine collection (baseline and
after vitamin C). The purpose of these measures was conversion to oxalate [16, 17, 33, 34]. To assess whether
our results could have been biased by an in vitro conver-to avoid any influence of diet (with respect to oxalate,
ascorbate, or calcium intake) on oxalate excretion other sion of ascorbate to oxalate, we performed an additional
experiment by collecting a spot urine from 15 controlthan vitamin C supplementation. Patients were then ran-
domly selected to receive either 1 g (500 mg twice a day) subjects 6 hours after intake of the vitamin C supplement
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Table 1. Mean urinary parameters before and after vitamin C supplements in calcium stone-forming patients and healthy subjects
Calcium stone forming Healthy subjects Calcium stone forming
Vitamin C, 1 g (N  23) Vitamin C, 1 g (N  20) Vitamin C, 2 g (N  24)
Pre Post Posta Pre Posta Pre Post Posta
Calcium mg/24 hours 15358 16980 188102 15599 15969 12944 15598 15781
Oxalate mg/24 hours 3112 5016b 4919b 2513c 3913b,c 3412 4821b 5919b
Sodium mEq/24 hours 20995 20383 ND 17257 ND 19483 19798 ND
Potassium mEq/24 hours 5925 6125 ND 5618 ND 5823 5427 ND
Urea g/24 hours 206 199 208 208 219 168 224 189
Creatinine mg/24 hours 1413346 1335423 1342481 1262536 1257441 1404404 1354424 1403512
Uric acid mg/24 hours 608219 415168b ND 465139c ND 484187 305109 ND
Magnesium mg/24 hours 8134 8132 8737 7031 7321 6928 7023 9142b
Citrate mg/24 hours 347208 380246 502287 432227 423225 376249 331197 392219
Tiselius index 0.910.65 1.430.7b 1.410.8b 0.910.46 1.50.69b 0.980.55 1.611.05b 1.621.0b
Volume 1997817 1924618 1899578 1250669 1308528 1634565 1649674 2104772b
XSD, a Collected under acid preservation. b vs. pre; c vs. calcium stone-forming P  0.05
(1 g) and dividing the samples into two aliquots, with or magnesium, and citrate and the calcium oxalate crystalli-
zation Tiselius index before and after the vitamin C sup-without EDTA (final concentration, 0.01 mol/L). The
results showed no difference in oxalate concentration plements in calcium stone-forming patients and healthy
subjects. Calcium stone-forming patients presented sig-between the samples with and without EDTA (28  23
vs. 26  21 mg/L, respectively, P  0.05, Wilcoxon test) nificantly higher mean values of urinary oxalate than
healthy subjects, both before (31  12 vs. 25  13 mg/24
hours, P  0.05) and after the vitamin C supplements
METHODS
(50  16 vs. 39  13 mg/24 hours, P  0.05). Calcium
Urinary parameters stone-forming patients also presented higher urinary uric
acid than healthy subjects (608 219 vs. 465 139 mg/24Urinary calcium was determined by atomic absorption
hours, P  0.05). Among healthy subjects, a significantspectrophotometry (Perkin-Elmer Atomic Spectropho-
increase in mean urinary oxalate level (39  13 vs. 25 tometer 290-B, Norwalk, CT, USA), oxalate by an enzy-
13 mg/24 hours, P  0.05) and in mean Tiselius indexmatic reaction using the Sigma Oxalate Diagnostic Kit
(1.5  0.69 vs. 0.91  0.46, P  0.05) was observed after(Sigma Chemical Co., St. Louis, MO, USA), sodium,
the vitamin C supplement in comparison to baseline,and potassium by flame photometry (Celm Fc-130), urea
with no changes in the remaining urinary parameters. Inby an enzymatic ultraviolet test, creatinine by Jaffe’s
calcium stone-forming patients, a significant increase inmethod [35], uric acid by an automated colorimetric en-
mean urinary oxalate was observed after supplementa-zymatic method (ABA VP), and citrate by an enzymatic
tion with either 1 g (50  16 vs. 31  12 mg/24 hours)assay using citrate lyase [36]. The urinary pH was ob-
or 2 g (48  21 vs. 34  12 mg/24 hours) vitamin Ctained in the second micturition after a 12-hour fast, and
compared to baseline, representing a 61% and 41% in-determined with a pH meter.
crement in mean oxaluria, respectively. This increase
Statistical analysis was also observed in urine samples further collected un-
der acid preservation for calcium stone-forming patientsResults are reported as mean  standard deviation
taking 1 g (49  19 vs. 31  12 mg/24 hours) or 2 g(SD). The Wilcoxon test was used to compare the results
vitamin C (59  19 vs. 34  12 mg/24 hours). There wasobtained after the vitamin C supplement to those ob-
a significant reduction of uric acid (415  168 vs. 608 tained before the supplement in the same group. The
219 mg/24 hours) in calcium stone-forming patients tak-Mann-Whitney test was used to compare the differences
ing 1 g, but this reduction has occurred within normalbetween the calcium stone-forming and healthy subject
limits, and was not observed among the patients takinggroups. The level of significance was defined as P 0.05.
2 g. Similarly, a significant increase in urinary magnesium
(91  42 vs. 69  28 mg/24 hours) in calcium stone-
RESULTS forming patients taking 2 g, but not in these taking 1 g
Mean age (37  14 vs. 37  16 years) and body mass was observed but again, such increase occurred within
index (27  5 vs. 24  4 kg/m2) did not differ between the range of normal limits. A significant increase in mean
calcium stone-forming patients and healthy subjects Tiselius index was observed after supplementation with
(data not shown in tables). either 1 g (0.92  0.65 vs. 1.43  0.70) or 2 g vitamin C
Table 1 shows the mean values of urinary calcium, (0.99  0.55 vs. 1.61  1.05). The remaining parameters
remained unchanged after vitamin C.oxalate, sodium, potassium, urea, creatinine, uric acid,
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Fig. 1. Urinary pH pre- and post-vitamin C supplements. Mean values
are indicated by horizontal bars.
Figure 1 shows that the mean urinary pH values before
vs. after1 or 2 g vitamin C supplementation in calcium
stone-forming patients were not significantly different.
The distribution of the urinary oxalate values in per-
Fig. 2. Box plots of urinary oxalate pre- and post-vitamin C with orcentiles is shown in Figure 2A and B.
without acid preservation in calcium stone-forming patients taking sup-
plements of either 1 gram (A) or 2 grams (B). The horizontal lines in
the box denote the 25th, 50th, and 75th percentile values. The errorDISCUSSION
bars denote the 5th and 95th percentile values. The symbols below the
5th percentile error bar denote the zero and 1st percentile values andThe assumption that the intake of high doses of vita-
the symbols above the 95th percentile error bar denote the 99th andmin C may be a major causative factor in the formation
100th percentile.
of renal calcium oxalate stones is old, dating back to the
finding that oxalate is one of the metabolic end products
of ascorbic acid excreted in the urine [37]. Several studies
have been conducted on healthy subjects to examine the ascorbic acid in four calcium stone-forming patients and
with Chalmers, Cowley, and Brown [3] who observed aeffect of vitamin C on urinary oxalate excretion using
different doses and periods of supplementation [6–17]. 79% increase in mean urinary oxalate after 2 g vitamin
C in 17 calcium stone-forming patients. Differences re-On the other hand, a reduced number of studies has been
performed to examine the effect of vitamin C on urinary garding the magnitude of urinary oxalate increase be-
tween the present data and these other studies may beoxalate in calcium stone-forming patients [2, 3, 20, 21].
However, the data from various investigations are con- ascribed to different oxalate assays and duration of sup-
plementation. Urivetzky, Kessaris, and Smith [2], usingtradictory, in part because of difficulties regarding oxa-
late assay techniques. Despite newer assays that mitigate the same assay as ours, also observed increases of 38%
and 107% in oxaluria following doses of 1 g and 2 g perthe in vitro conversion of ascorbic acid to oxalate, contro-
versy still remains, with some studies suggesting that day in 15 calcium stone-forming patients, respectively.
Conversely, no increase in urinary oxalate after a singlevitamin C leads to an increase in oxaluria [14], whereas
others do not support this observation [13, 15, 16]. dose of 1 g vitamin C was detected by Heckers et al
[21], who regrettably did not indicate the assay used forIn the present study, a significant increase of 61%
and 41% was observed in mean urinary oxalate after urinary oxalate determination.
In the present series, the significant increase in urinarysupplementation with 1 or 2 g vitamin C, respectively,
in calcium stone-forming patients. The lack of a further oxalate observed even in the urine specimens collected
in a gallon containing acid preservative minimizes theincrease on urinary oxalate after 2 g vitamin C may be
ascribed to a saturable transport mechanism leading to possibility that the increase in oxaluria after vitamin C
was due to the in vitro nonenzymatic conversion of ascor-a reduced relative absorption capacity with increasing
intakes of the compound [5, 38]. Our findings are in bate to oxalate since HCl reduces the urinary pH to values
around 1. According to Auer, Auer, and Rodgers [16],accordance with Tiselius et al [20] who observed a 48%
increase in oxaluria following a dose of 1 g per day of the possibility that urinary oxalate measurements may be
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falsely elevated by the presence of high urinary ascorbate allowance. Vitamin C does not seem to be an efficient
urinary acidifier in calcium stone-forming patients.must be considered. However, Liebman et al [15] re-
ported that whereas 2 g vitamin C supplement produced
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